Body cells constantly present peptides on their surface, indicating the current state of the cell. Immune cells can recognize if a cell presents normal or abnormal peptides and use this information to determine and eliminate defective cells. Abnormal peptides, so-called neoantigens, are also produced by tumor mutations and represent targets for immune surveillance and tumor elimination.
CeGaT’s CancerNeo® enables the analysis of a patient’s tumor exome to detect tumor-specific (somatic) mutations, identifies the HLA-types, and predicts neoantigens. The expression of these neoantigens is confirmed by whole RNA sequencing (transcriptome) from the same tumor sample. Thus, CeGaT’s CancerNeo® provides the insights required for the design of personalized cancer vaccines – a powerful tool to boost the immune system’s response to cancer cells.
- Processing time: 2-3 weeks after sample receipt
- Highest confidentiality and quality standards
- Our customer service accompanies you at each single step